Early prediction of response to neoadjuvant chemotherapy using contrast-enhanced ultrasound in breast cancer

Juan Peng, MDa, Huan Pu, MDb, Yan Jia, MDc, Chuang Chen, MDc, Xiao-Kang Ke, MDb, Qing Zhou, MDa,∗

Abstract
Early prediction of non-response is essential in order to avoid inefficient treatments. The objective of this study was to determine the contrast-enhanced ultrasound (CEUS) for early predicting pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients.

Between March 2018 and October 2019, 93 consecutive patients with histologically proven breast cancer scheduled for NAC were enrolled. Conventional ultrasound and CEUS imaging were performed before NAC and after two cycles of NAC. CEUS parameters were compared with pathologic response. Multiple logistic regression analyses were utilized to explore CEUS parameters to predict pCR, and receiver operating characteristic analysis was used to evaluate the predictive ability.

Therapeutic response was obtained from 25 (27%) patients with pCR and 68 (73%) with non-pCR. Compared to non-pCR, pCR cases have a significantly higher proportion of homogeneous enhancement feature (56% vs 14%, P < .001) and centripetal enhancement (52% vs 23%, P = .012). A significant decrease in peak intensity (PI) was observed after two cycles of NAC. Compared with non-pCR patients, the kinetic parameters PI change (PI%) was higher in pCR patients (P < .001). Multiple logistic regression demonstrated two independent predictors of pCR: internal homogeneity (odds ratio, 4.85; 95% confidence interval: 1.20–19.65; P = .027) and PI% (odds ratio, 1.08; 95% confidence interval: 1.02–1.15; P = .007). In receiver operating characteristic curve analysis, internal homogeneity and PI%, with area under curve of 0.71 and 0.84, predicted pCR with sensitivity (56%, 95%) and specificity (85%, 70%), respectively.

Internal homogeneity and PI% of CEUS may be useful in the noninvasive early prediction of pCR in patients with breast cancer.

Abbreviations: AS = ascending slope, AUC = area under curve, CEUS = contrast-enhanced ultrasound, CI = confidence interval, NAC = neoadjuvant chemotherapy, pCR = pathologic complete response, PI = peak intensity, ROC = receiver operating characteristic, TTP = time to peak, WIT = wash-in time.

Keywords: breast cancer, contrast-enhanced ultrasound, neoadjuvant chemotherapy, predictor

1. Introduction
Neoadjuvant chemotherapy (NAC) before surgery is widely used in patients with locally advanced breast cancer. A pathological complete response (pCR) after NAC is assumed to be associated with better outcomes, including increased overall survival and free disease survival rates.[1,2] Recently, pCR rates have increased because of the wide availability of more effective chemotherapy agents and targeted drugs. Accurate identification of tumor response to NAC would be of significant clinical relevance for a refined therapy decision, individually tailored surgical approaches, as well as for improving patient’s prognosis.[3–5] After the final NAC, non-responders inevitably suffered from the side-effects of large doses of chemotherapeutic agents. Therefore, accumulating studies have sought to identify early predictive factors of pCR in breast cancer, including clinic-pathological factors and imaging parameters.

Contrast-enhanced ultrasound (CEUS) has gained extensive interest in recent years for its ability to collect macro- and microvascular information in various tumors.[6–9] Imaging of blood flow serves as a crucial alternative for monitoring the treatment effects of chemotherapeutic drugs. Early alteration in neovascular net of breast tumors during NAC may reflect in altered pharmacokinetics of contrast agents detected by CEUS, making it possible to assess early response to therapeutic drugs. To our knowledge, few studies have determined the performance of CEUS in predicting pathologic outcomes in patients with breast cancer, and most of those studies used quantitative parameters only, including a relatively small study population.[10–13]

The purpose of our study was to investigate whether CEUS qualitative and quantitative parameters acquired baseline and
following two cycles of NAC can be utilized to predict pathologic response in breast cancer patients.

2. Methods

2.1. Patient population

The clinical and imaging records of 93 breast cancer patients with the approval of the ethics committee of the Renmin hospital of Wuhan University, China and informed consent provided were retrospectively reviewed. The 93 consecutive patients were enrolled, who proven breast cancer according to positive results on core needle biopsy and scheduled for NAC from March 2018 to October 2019. Exclusion criteria were contraindications to the contrast agent, such as a history of cardiac failure, respiratory disorder, or hypersensitivity.

2.2. NAC regimen

All patients received 6 or 8 cycles of NAC prior to breast surgery, and each chemotherapy cycle was 21 days. The NAC regimens were either taxane-based, anthracycline-based or anthracycline and taxane-based. The course of treatment includes 6 or 8 chemotherapy cycles. The chemotherapy regimen comprised 6 or 8 cycles of FEC (fluorouracil, 500mg/m²; epirubicin, 75–100mg/m²; cyclophosphamide, 500mg/m²). Patients received PEC for 6 or 8 cycles (paclitaxel, 175mg/m²; epirubicin, 60mg/m²; cyclophosphamide, 60mg/m²). Additionally, human epidermal growth factor receptor 2-positive (HER2+) patients were treated with trastuzumab.

2.3. Conventional ultrasound and CEUS

All patients underwent conventional ultrasound and CEUS within a week prior to the initiation of NAC (baseline) and after two cycles of NAC. The flow chart of NAC is shown (Fig. 1). The examinations were performed by two experienced breast radiologists. Conventional ultrasound images were initially acquired using Arietta 70 ultrasonic device (Hitachi-Aloka Medical, Tokyo, Japan) with a 5–13MHz transducer. CEUS was performed subsequently using the same transducer at a low mechanical index (MI < 0.10). The contrast agent, SonoVue (Bracco, Milan, Italy) was intravenously administered at a dose of 4.8 mL as bolus and was subsequently flushed with 10mL of saline. The examination was documented in a 3-minutes long clip, starting at the beginning of the bolus injection.

Classification of the enhancement patterns was defined based on the previous literature and our clinical experience. Enhancement degree was assessed compared to surrounding normal breast tissue at the peak time and was classified as hypo-, iso-, or hyper-enhancement. The enhancement order was also assessed and was classified as centripetal, centrifugal or diffused enhancement. Centripetal enhancement, intensity of enhancement was more apparent in the center than the periphery and center of lesion site was enhanced. Centrifugal enhancement, the periphery of the lesion site was enhanced, however, the center of the lesion was not marked enhancement. Diffused enhancement was the proper classification if the lesion was diffusely enhanced without obvious order. Enhancement margin was either distinct (>50% of the lesion circumference was clearly visible) or indistinct (>50% of the lesion was spiculated or angular). Internal homogeneity was classified as homogeneous or heterogeneous enhancement. Homogeneous enhancement, all areas in the lesion site were homogeneously and enhanced with almost the same enhancement intensity. Heterogeneous enhancement, the enhancement areas were distributed unevenly in the lesion with different intensities. The presence or absence of perfusion defect and radial or penetrating vessels were recorded.

Quantitative parameters of the time intensity curve were obtained with Arietta 70 ultrasonic device software (Hitachi-Aloka Medical) (Fig. 2). A region of interest (ROI) was manually drawn in the area of the strongest enhancement. Quantitative parameters were defined using previously described criteria as follows. Wash-in time (WIT) was the time when the first microbubble was seen entering the lesion. Peak intensity (PI) was the maximum intensity of the time-intensity curve. PI in breast cancer lesions on CEUS images was calculated as maximum intensity minus baseline intensity. Time to peak (TTP) was the time needed to reach peak intensity beginning from the moment the first microbubble reached the lesion. Ascending slope (AS) was the maximum wash-in velocity of the contrast medium, which was calculated as PI divided by TTP.

2.4. Pathologic assessment

The postoperative specimens were examined by dedicated pathologists in breast cancer, and a binary outcome was assessed: pCR versus non-pCR. The pCR was defined as the absence of any invasive component, or residual ductal carcinoma in situ (DCIS) component in the specimen obtained from surgery. A non-pCR was the presence of microscopic invasive tumor in the final pathology. Lymph node status was not taken into account. After the course of NAC, all patients underwent either

---

**Figure 1.** Flow chart of NAC. Each cycle lasted for 21 days and surgical excision was performed within 10 days after 6 or 8 cycles. The parameters of CEUS were recorded. CEUS = contrast-enhanced ultrasound, NAC = neoadjuvant chemotherapy.
mastectomy (73 patients) or breast-conserving therapy (20 patients) and pathological postoperative evaluation was performed at our institution in all cases. Tumors were classified into three subgroups according to their receptor markers: HR+/HER2- (Luminal), HR-/HER2+ (HER2 positive) and HR-/HER2- (Triple-receptor negative). Hormone receptor (HR) status was defined using immunohistochemistry according to Harvey et al and Leake et al. HER2 status was determined according to the American Society of Clinical Oncology/College of American Pathologists guideline recommendations using immunohistochemistry and fluorescence in situ hybridization (FISH).

2.5. Statistical analysis

Categorical variables were compared using the Chi-square test or Fisher exact test between patients with pCR and non-pCR. The continuous variables were compared using unpaired t-test between the two groups. Changes in the quantitative parameters before and after 2 cycles of NAC were calculated using the following formula: 
\[
\left(\frac{\text{value before NAC} - \text{value after 2 cycles of NAC}}{\text{value before NAC}}\right) \times 100\%
\]
The continuous variables were compared using Wilcoxon rank sum test between two time points. Multiple logistic regression analyses were performed to test the independent factors for prediction of pCR. Models were adjusted for age, and we excluded variables from univariable analysis if their between-group differences were not significant. The receiver operator characteristic (ROC) curve analysis was performed to test the ability of each parameter to predict pCR. Statistical analysis was performed IBM SPSS Statistics, version 21.0 (IBM, Armonk, NY). A P value <.05 was considered statistically significant.

**Table 1**

| Characteristic                          | pCR (n = 25) (%) | non-pCR (n = 68) (%) | P value |
|----------------------------------------|-----------------|----------------------|---------|
| Age (yr)                               |                 |                      | .639    |
| Mean ± SD                             | 47.7 ± 10.2     | 48.8 ± 10.2          |         |
| Menopause status                       |                 |                      | .456    |
| Premenopausal                          | 9 (10)          | 19 (20)              |         |
| Postmenopausal                         | 16 (17)         | 49 (53)              |         |
| Tumor diameter (cm)                    |                 |                      | .122    |
| < 2                                    | 2 (2)           | 9 (10)               |         |
| 2–5                                    | 23 (24)         | 50 (54)              |         |
| > 5                                    | 0 (0)           | 9 (10)               |         |
| Tumor histology                        |                 |                      | 1.000   |
| IDC                                    | 23 (24)         | 61 (66)              |         |
| ILC                                    | 2 (2)           | 7 (8)                |         |
| Clinical stage                         |                 |                      | .417    |
| II                                     | 8 (9)           | 15 (16)              |         |
| III                                    | 17 (18)         | 53 (57)              |         |
| Subtype                                |                 |                      | .337    |
| Luminal                                | 4 (4)           | 20 (22)              |         |
| HER2 positive                          | 12 (13)         | 23 (24)              |         |
| Triple-receptor negative               | 9 (10)          | 25 (27)              |         |
| Ki67 labeling index                    |                 |                      | .338    |
| ≤ 20%                                  | 2 (2)           | 12 (13)              |         |
| > 20%                                  | 23 (24)         | 56 (61)              |         |
| Lymph node status                      |                 |                      | .004    |
| Positive                               | 16 (17)         | 20 (22)              |         |
| Negative                               | 9 (10)          | 48 (51)              |         |

HER2 = human epidermal growth factor receptor 2, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, pCR = pathologic complete response, SD = standard deviation.
3. Results

3.1. Clinical and pathological characteristics of breast cancer patients

The mean age of the 93 women with breast cancer was 48 years (range, 29–70 years). 84 (90%) patients were invasive ductal carcinomas and 9 (10%) were invasive lobular carcinomas. 36 (39%) patients had axillary lymph node involvement, 79 (85%) of whom had a Ki-67 labeling index of more than 20%. HER2 positive is the most common subtype and accounts for 37% of all breast cancer, it is followed by triple-receptor negative 34 (37%) and luminal subtype 24 (26%) in our study. The non-pCR cases have a much higher proportion of lymph node metastasis compared to pCR cases (71% vs 35%, \( P = .004 \)). There were no differences in age, menopause status, tumor diameter, clinical tumor stage, immunohistochemical subtype and level of Ki-67 expression between pCR and non-pCR groups (all \( P > .05 \)). The patient’s characteristics are summarized (Table 1).

3.2. CEUS before NAC

Of the 93 breast lesions, 64 (68%) demonstrated signs of hyper-enhancement, and 29 (32%) showed signs of iso- or hypo-enhancement. There were 29 (31%) lesions that showed centripetal enhancement and 64 (69%) that presented centrifugal or diffuse enhancement. Distinct tumor margin was observed in 36 (38%) lesions. Heterogeneous enhancement was seen in 69 (74%) lesions, and homogeneous enhancement was found in 24 (26%) lesions. A perfusion defect was observed in 25 (27%) lesions. Radial or penetrating vessels were found in 26 (29%) lesions. Compared to non-pCR cases, pCR cases have a significantly higher proportion of homogeneous enhancement feature (56% vs 14%, \( P < .001 \)) and centripetal enhancement (52% vs 23%, \( P = .012 \)). No differences were observed between pCR and non-pCR patients in terms of other CEUS features (all \( P > .05 \)). Pre-NAC CEUS pattern findings are presented (Table 2).

3.3. CEUS quantitative parameters after two cycles of NAC

63 patients underwent CEUS after two cycles of NAC. A significant decrease in PI was present after two cycles of NAC. And a trend to decrease in tumor diameter and AS, and a trend to increase in TTP and WIT were observed, those changes are not statistically different (Table 3). Compared with non-pCR patients, the kinetic parameters PI % was higher in pCR patients. However, parameters of WIT, PI, TTP, AS, diameter, WIT%, TTP%, AS% and diameter% showed no differences between pCR and non-pCR patients (all \( P > .05 \)). The change of quantitative parameters was shown in pCR and non-pCR patients, respectively (Figs. 3 and 4).

| Table 2 |
| Distribution of enhancement pattern for different pathological response. |
| Enhancement pattern | pCR (n = 25) (%) | non-pCR (n = 68) (%) | \( P \) value |
|----------------------|------------------|---------------------|---------------|
| Enhancement degree   | Hyper-enhancement | 16 (17)             | 48 (51)       | .616          |
|                      | Iso- or hypo-enhancement | 9 (10) | 20 (22) |
| Enhancement order    | Centripetal       | 13 (14)             | 16 (17)       | .012          |
|                      | Centrifugal or diffuse | 12 (13) | 52 (56) |
| Enhancement margin   | Distinct          | 13 (14)             | 23 (24)       | .150          |
|                      | Indistinct        | 12 (13)             | 45 (49)       | .000          |
| Internal homogeneity | Homogeneous       | 14 (15)             | 10 (11)       | .292          |
|                      | Heterogeneous     | 11 (12)             | 58 (62)       | .610          |
| Perfusion defect     | Present           | 9 (10)              | 16 (17)       |               |
|                      | Absent            | 16 (17)             | 52 (56)       |               |
| Radial or penetrating vessel | Present | 8 (9) | 18 (20) |
|                      | Absent            | 17 (18)             | 50 (53)       |               |

pCR = pathologic complete response.

| Table 3 |
| Relationship between quantitative parameters and pathological complete response. |
| Parameter | Pre-NAC (pCR (n = 25) non-pCR (n = 68)) | \( P \) value | 2 cycles NAC (pCR (n = 20) non-pCR (n = 43)) | \( P \) value | \% Change (pCR (n = 20) non-pCR (n = 43)) | \( P \) value |
|-----------|------------------------------------------|---------------|-----------------------------------------------|---------------|------------------------------------------|---------------|
| WIT (s)   | 12.3 ± 4.9 | 10.8 ± 5.5 | .070 | 12.7 ± 2.9 | 11.0 ± 3.0 | .055 | 36.2 ± 25.1 | 31.2 ± 20.0 | .535 |
| PI        | 38.1 ± 6.9 | 40.0 ± 7.9 | .207 | 32.8 ± 3.4 | 34.3 ± 4.7 | .031 | 22.1 ± 10.5 | 10.7 ± 10.8 | .000 |
| TTP(s)    | 12.4 ± 3.2 | 12.1 ± 5.7 | .397 | 13.0 ± 3.4 | 14.0 ± 3.8 | .280 | 22.5 ± 19.1 | 36.8 ± 32.9 | .068 |
| AS        | 3.1 ± 0.7  | 3.6 ± 1.2  | .151 | 2.6 ± 0.6  | 2.7 ± 0.8  | .701 | 29.6 ± 12.2 | 31.9 ± 28.0 | .701 |
| Diameter (cm) | 3.2 ± 1.0 | 3.8 ± 1.8 | .323 | 2.4 ± 0.9  | 2.9 ± 1.4  | .095 | 26.3 ± 17.5 | 24.9 ± 16.7 | .751 |

AS = ascending slope, PI = peak intensity, TTP = time to peak, WIT = wash-in time.
3.4. Predictors of pCR and ROC analysis

The pCR was achieved in 25 (27%) patients, as determined by pathologic specimens. In univariable logistic regression analysis, internal homogeneity \((P < .001)\), centripetal enhancement order \((P = .012)\), PI (after two cycles of NAC, \(P = .031\)) and PI% (\(P < .001\)) were associated with pCR. After adjusting for age, the multivariable model showed that PI% (odds ratio, 1.08; 95% confidence interval [CI], 1.02–1.15; \(P = .007\)) and internal homogeneity (odds ratio, 4.85; 95% CI, 1.20–19.65; \(P = .027\)) were independent predictors of pCR (Table 4).

To evaluate the contribution of CEUS parameters to the prediction of pCR, the ROC curve analysis was performed. The area under curve of ROC for PI% after two cycles of NAC in the prediction of pCR was 0.84 (95% CI: 0.73–0.94), that yielded 95% sensitivity and 70% specificity. The area under curve for internal homogeneity was 0.71 (95% CI: 0.61–0.81) with 56% sensitivity and 85% specificity (Table 5 and Fig. 5).

4. Discussion

The accurate prediction of the response to NAC at an earlier stage has the potential to contribute to breast cancer patient prognosis. Among the independent factors extracted from CEUS examinations in the present study, an early PI change (PI%) and internal homogeneity were independent predictors for pCR.

Regarding the feasibility of clinical practice in China, the experts strongly recommends that ultrasound should be utilized to assess the primary breast mass and regional lymph nodes every two cycles of NAC.\(^{[22]}\) Consequently, we selected the completion of two cycles of NAC as the timing of ultrasound imaging for predicting for pCR in this study.

PI reflects the quantity of contrast agent microbubbles in the vascular bed of the lesion, which is associated with the degree of vascularization. Our results are consistent with previous studies, better tumor response was associated with a larger decrement in PI in patients with breast cancer undergoing NAC.\(^{[10]}\) The time point for CEUS assessment in our study was much earlier than previous CEUS studies (after two cycle of NAC vs completion of NAC). Theoretically, our results are more helpful for NAC of breast cancer. The possible explanation of the PI% in pCR is that in the early stages of NAC demonstrated a reduction in blood flow, which in turn led to slower wash-in of contrast agent reflecting good efficacy of chemotherapeutic agents.\(^{[23]}\)

The multivariable logistic regression analysis also revealed that homogeneous enhancement pattern before NAC was a significant predictor for pCR. This result is consistent with previous dynamic contrast-enhanced magnetic resonance imaging (MRI) study. The study reported that patients in the pCR were more likely to present homogeneous enhancement than were those in the non-pCR group.\(^{[24]}\) However, caution is indicated when...
comparing results from CEUS with those from MRI perfusion study, as the parameters are dependent on different pharmacokinetics of contrast agents and mathematical models. The possible explanation for a heterogeneous enhancement feature being more associated with non-pCR than homogeneous enhancement is that its pathologic features, including its higher histologic tumor grade or increased vascular endothelial growth factor expression, which is associated with a poor prognosis, may have been reflected in the enhancement feature.\[25,26\] Previous research suggested chemotherapeutic drugs acted directly on cancer cells and microvasculature to affect a clinically relevant alteration in tumor size. Reduction in tumor size is a late demonstration of effective treatment and may take several weeks to occur.\[27\] Consistent with the findings of previous studies, our data also showed at an earlier stage tumor diameter remains unchanged despite a positive functional response to treatment. We found no significant association between the other CEUS quantitative parameters excluding PI% and pCR in our study.

![Figure 4. A 56-year-old woman with breast cancer. (A) Before NAC, a CEUS image obtained 34 s after contrast agent injection showing heterogeneous hyper-enhancement with an indistinct margin. The largest diameter of the tumor was 4.8 cm. The TIC at CEUS showed strong and rapid enhancement. WIT = 13.0, PI = 44.5, TTP = 10.2, AS = 4.4. (B) After 2 cycles NAC, CEUS showed a decrease in the tumor size to 4.5 cm, heterogeneous hyper-enhancement with indistinct margin. The TIC at CEUS also showed strong and rapid enhancement. WIT = 11.2, PI = 42.5, TTP = 12.4, AS = 3.4. (C) The pathological specimen with non-pCR, revealed nest of tumor cells and surrounding dense fibrous tissue (magnification in left panel, ×100; the right panel showed the windows from the left panel at a magnification of ×400). AS = ascending slope, CEUS = contrast-enhanced ultrasound, NAC = neoadjuvant chemotherapy, pCR = pathologic complete response, PI = peak intensity, TIC = time intensity curve, TTP = time to peak, WIT = wash-in time.](image)

### Table 4

| Variable               | Univariable OR (95%CI) | P value | Multivariable OR (95%CI) | P value |
|------------------------|------------------------|---------|--------------------------|---------|
| Enhancement order      | 3.52 (1.34–9.23)       | .011    | 4.85 (1.20–19.65)        | .027    |
| Internal homogeneity   | 7.38 (2.61–20.81)      | .001    | 4.85 (1.20–19.65)        | .027    |
| PI%                    | 1.09 (1.03–1.15)       | .002    | 1.08 (1.02–1.15)         | .007    |

CI = confidence interval, OR = odds ratio, PI = peak intensity.
population. However, Wan et al reported that CEUS quantitative parameters (after completion of NAC) were risk factors for predicting pCR in breast cancer patients. The reason for this discrepancy is not completely clear, but it may be ascribed to differences in imaging time, or patient selection.

Our study had some limitations. First, our study included patients with various subtypes of breast cancer. There were some different chemotherapy regimens among the different subtype patients. Second, selection of the ROI and classification of the enhancement patterns were subjective. Third, the small sample size reduced the stability of the regression models, and the role of different CEUS parameters on the reflection of predictors could not be thoroughly investigated. Further extensive study is needed. Fourth, the PI% also suffers from overlapping error margins in the before and after NAC groups.

5. Conclusion

Internal homogeneity and PI% on CEUS may provide early identification of pathologic responsiveness to NAC, which may be used as biomarkers of tumor response in breast cancer patients who are undergoing NAC.

Acknowledgments

We gratefully acknowledge and thank all participants who contributed to the study.

Author contributions

Conceptualization: Yan Jia, Qing Zhou.
Data curation: Juan Peng, Huan Pu.
Final approval of manuscript: all authors.
Formal analysis: Yan Jia, Qing Zhou.
Investigation: Juan Peng, Huan Pu, Yan Jia.
Methodology: Juan Peng, Huan Pu, Xiao-Kang Ke, Qing Zhou.
Resources: Yan Jia, Chuang Chen.
Software: Juan Peng, Xiao-Kang Ke.
Supervision: Qing Zhou.
Validation: Chuang Chen.
Visualization: Huan Pu.
Writing – original draft: Juan Peng.
Writing – review & editing: Huan Pu, Chuang Chen, Xiao-Kang Ke, Qing Zhou.

References

[1] Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019–27.
[2] van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224–37.
[3] Early Breast Cancer Trialists’ Collaborative Group. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018;19:27–39.

[4] Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483–93.

[5] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–72.

[6] Pei XQ, Liu LZ, Zheng W, et al. Contrast-enhanced ultrasonography and dynamic contrast-enhanced magnetic resonance imaging for the early prediction of bevacizumab aggressiveness. Eur Radiol 2018;28:1949–58.

[7] Hoyt K, Sorace A, Saini R. Quantitative mapping of tumor vascularity using volumetric contrast-enhanced ultrasound. Invest Radiol 2012;47:167–74.

[8] Baur ADJ, Schwabe J, Rogasch J, et al. A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness. Eur Radiol 2018;28:1949–60.

[9] Amadori M, Barone D, Scarpi E, et al. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol 2018;28:2969–78.

[10] Wan CF, Liu XS, Wang L, Zhang J, Lu JS, Li FH. Quantitative contrast-enhanced ultrasound evaluation of pathological complete response in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy. Eur J Radiol 2018;103:118–23.

[11] Amioka A, Masumoto N, Gouda N, et al. Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. Jpn J Clin Oncol 2016;46:303–9.

[12] Gu LS, Zhang R, Wang Y, et al. Characteristics of contrast-enhanced ultrasonography and strain elastography of locally advanced breast cancer. J Thorac Dis 2019;11:5274–89.

[13] Kim Y, Kim SH, Song BJ, et al. Early prediction of response to neoadjuvant chemotherapy using dynamic contrast-enhanced MRI and ultrasound in breast cancer. Korean J Radiol 2018;19:682–91.

[14] Li X, Li Y, Zhu Y, Fu L, Liu P. Association between enhancement patterns and parameters of contrast-enhanced ultrasound and microvessel distribution in breast cancer. Oncol Lett 2018;15:5643–9.

[15] Zhao H, Xu R, Ouyang Q, Chen L, Dong B, Huihua Y. Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. Eur J Radiol 2010;73:288–93.

[16] Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;25:2650–5.

[17] Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91–101.

[18] Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678–85.

[19] Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474–81.

[20] Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000;53:634–5.

[21] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18–43.

[22] Chinese Group of Neoadjuvant Therapy for Breast Cancer. Expert consensus on neoadjuvant therapy for breast cancer in China (2019 edition). China Oncology 2019;5:390–5.

[23] Darland DC, D’Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest 1999;103:157–8.

[24] Eom HJ, Cha JH, Choi WJ, Chae EY, Shin HJ, Kim HH. Predictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancer. AJR Am J Roentgenol 2017;208:W225–30.

[25] Chang YW, Kwon KH, Choi DL, et al. Magnetic resonance imaging of breast cancer and correlation with prognostic factors. Acta Radiol 2009;50:990–8.

[26] Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006;239:351–60.

[27] Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006;24:843–7.